WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group (Q44097808)

29 November 2017

title

WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group (English)

1 reference

29 November 2017

1 reference

acute myeloid leukemia

1 reference

childhood acute myeloid leukemia

inferred from title

1 reference

Hirozumi Sano

1

1 reference

29 November 2017

Akira Shimada

2

1 reference

29 November 2017

Ken Tabuchi

3

1 reference

29 November 2017

Tomohiko Taki

4

1 reference

29 November 2017

Chisato Murata

5

1 reference

29 November 2017

Myoung-ja Park

6

1 reference

29 November 2017

Kentaro Ohki

7

1 reference

29 November 2017

Manabu Sotomatsu

8

1 reference

29 November 2017

Souichi Adachi

9

1 reference

29 November 2017

Akio Tawa

10

1 reference

29 November 2017

Ryoji Kobayashi

11

1 reference

29 November 2017

Keizo Horibe

12

1 reference

29 November 2017

Masahiro Tsuchida

13

1 reference

29 November 2017

Ryoji Hanada

14

1 reference

29 November 2017

Ichiro Tsukimoto

15

1 reference

29 November 2017

Yasuhide Hayashi

16

1 reference

29 November 2017

publication date

27 August 2013

1 reference

International Journal of Hematology

29 November 2017

published in

1 reference

29 November 2017

volume

98

1 reference

29 November 2017

issue

4

1 reference

29 November 2017

page(s)

437-445

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-013-1409-6

29 November 2017

exact match

0 references

cites work

Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

A cell cycle regulator potentially involved in genesis of many tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Mutations and altered expression of p16INK4 in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Cooperating gene mutations in acute myeloid leukemia: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

High Expression Levels of theETS-Related Gene,ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1409-6

Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia

21 January 2018

1 reference

12 December 2020

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

12 December 2020

Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children

1 reference

12 December 2020

Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis.

1 reference

12 December 2020

A tumor suppressor and oncogene: the WT1 story.

1 reference

12 December 2020

Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group

1 reference

12 December 2020

10.1007/S12185-013-1409-6

Identifiers

DOI

1 reference

29 November 2017

1 reference